Top

Published in:

01-03-2004 | Review

Immunological inhibition of carcinogenesis

Authors: Michela Spadaro, Stefania Lanzardo, Claudia Curcio, Guido Forni, Federica Cavallo

Published in: Cancer Immunology, Immunotherapy | Issue 3/2004

Abstract

The combination of new information provided by fundamental immunology, along with the refinement of genetic engineering techniques has given scientists the capacity to produce vaccines able to inhibit the growth of most if not every transplantable tumor. However, when faced with already established tumors, vaccines fail to afford any significant protection. Many studies are underway which seek to overcome this gloomy situation. However, another possibility is to follow the indications provided by a large quantity of experimental data and to evaluate the possibility of using immunotherapy to prevent the initial stages of tumor growth. Is it possible to prevent an autologous tumor by means of a vaccination performed before tumor onset? Could antitumor vaccines be a new form of preventive medicine in the wake of Jenner, Pasteur, and other pioneers? In this paper it is our intention to review the results obtained by our laboratory in the attempt to use natural and adaptive immunity in the control of carcinogenesis. Natural immunity boosted by IL-12 and IL-2 significantly hampers the progression of mammary lesions occurring in HER-2/neu transgenic mice genetically predestined to develop lethal mammary carcinomas. Specific immunity elicited by DNA vaccination provides a much stronger inhibition of the development of mammary lesions, and a significant number of transgenic mice are tumor free at 1 year of age. These experimental data suggest the possibility of using immunity as a means of controlling preneoplastic lesions and protecting healthy persons at risk of developing cancer.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127CrossRefPubMed

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 257:539CrossRef

Bargmann CI, Weinberg RA (1988) Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci U S A. 85:5394

Baselga J (2001) Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61:14CrossRef

Bishop JS, Thull NM, Matar M, Quezada A, Munger WE, Batten TL, Muller S, and Pericle F (2000) Anti-tumoral effect of a non-viral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil. Cancer Gene Ther 7:1165CrossRefPubMed

Blezinger P, Freimark BD, Matar M, Wilson E, Singhal A, Min W, Nordstrom JL, Pericle F (1999) Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 10:723PubMed

Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S (2000) Antitumor vaccination: where we stand. Haematologica 85:1172PubMed

Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589PubMed

Boggio K., Di Carlo E., Rovero S, Cavallo F, Quaglino E, Lollini P-L, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G (2000) Ability of systemic IL-12 to hamper progressive stages of mammary carcinogenesis in Her2/neu trangenic mice. Cancer Res 60:359PubMed

10.

Boon T (1983) Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res 39:121PubMed

11.

Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Nanni P, Amici A, Di Carlo E, Musiani P, Giovarelli M, Forni G (2003) LAG-3 enables DNA vaccination to persistently prevent mammari carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63:2518PubMed

12.

Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE (2000) The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19:968PubMed

13.

Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Forni M, Modesti A, Forni G (1993) Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinomas. Cancer Res 53:5067PubMed

14.

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G (1997) Antitumor efficacy of adenocarcinoma cells engeneered to produce interleukin 12 (IL-12) or other cytokines compared with exogeneous IL-12. J Natl Cancer Inst 89:1049CrossRefPubMed

15.

Cavallo F, Di Carlo E, Butera M, Verrua R, Colombo MP, Musiani P, Forni G (1999) Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res 59:414PubMed

16.

Cavallo F, Quaglino E, Cifaldi L, Di Carlo E, Andrè A, Bernabei P, Musiani P, Forni G and Calogero RA (2001) IL12-activated lymphocytes influence tumor genetic programs. Cancer Res 61:3518PubMed

17.

Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini P-L, Wolf S, Boggio K, Forni G, Cavallo F (2001) A light, nontoxic IL-12 protocol inhibits Her2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia. Cancer Res 61:2809PubMed

18.

Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM (1998) Tumor cell rresponse to IFN-gamma affect tumorigenicity and response to IL-12 therapy and angiogenesis. Immunity 9:25PubMed

19.

Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med 193:F23

20.

Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G (2003) Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 111:1161CrossRefPubMed

21.

De Stefani A, Forni G, Ragona R, Cavallo F, Bussi M, Usai A, Badellino F, Cortesina G (2002) Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95:90CrossRefPubMed

22.

Di Carlo E, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P, Forni G, Musiani P (1999) Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79:1261PubMed

23.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991CrossRefPubMed

24.

Forni G, Lollini P-L, Musiani P, Colombo MP (2000) Immunoprevention of cancer: is the time ripe? Cancer Res 60:2571PubMed

25.

Garcia-Lora A, Algarra I, Collado A, Garrido F (2003) Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 30:177CrossRefPubMed

26.

Grimm EA (1986) Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta 865:267CrossRefPubMed

27.

Gullick WJ, love SB,Wright C, Barnes DM, Gusterson B, Harris AL (1991) C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434PubMed

28.

Hardy B, Yampolski I, Kovjazin R, Galli M, Novogrodsky A (1994) A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res 54:5793PubMed

29.

Klein G, Sjogren HO, Klein E (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561

30.

Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J (2000) Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165:5713PubMed

31.

Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hjnes NE (2000) ErbB2 potentiates breast tumor proliferation through modulation of p27 (Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20:3210CrossRefPubMed

32.

Lewis Phillips GD, McMurtrey AE, Schroeder K, Fendly BM (1998) Diverse activities of anti-HER2 monoclonal antibodies: from growth inhibition to induction of apoptosis. Proc Am Assoc Cancer Res 39:143

33.

Lollini P-L, De Giovanni C, Nicoletti G, Di Carlo E, Musiani P, Nanni P, Forni G (2002) Immunoprevention of colorectal cancer: a future possibility? Gastroenterol Clin North Am 31:1001–14PubMed

34.

Muller WJ, Sinn E, Wallance R, Pattengale PK, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105PubMed

35.

Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini P-L (2001) Combined allogeneic tumor cell vaccination and systemic IL-12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1195–1205PubMed

36.

Noguchi Y, Jungbluth A, Richards EC, Old LJ (1996) Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A 93:11798–11801CrossRefPubMed

37.

Park BW, O’Rourke DM, Wang Q, Davis JG, Post A, Qian X, Greene MI (1999) Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB recepotr tyrosine kinases. Proc Natl Acad Sci U S A 96:6434CrossRefPubMed

38.

Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627PubMed

39.

Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133PubMed

40.

Rovero S, Boggio K, Di Carlo E, Amici A, Quaglino E, Porcedda P, Musiani P, Forni G (2001) Insertion of the DNA for the 163–171 peptide of IL1β enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther 8:447PubMed

41.

Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC (1991) p185her2 signal transduction in breast cancer cells. J Biol Chem 266:14300PubMed

42.

Shau H, Kim A, Golub H (1992) Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukocyte Biol 51:343PubMed

43.

Shih C, Padhy LC, Murray M, Weinberg RA (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261PubMed

44.

Smith RT, Landy M (eds) (1970) Immune surveillance. Academic Press, New York

45.

Smyth MJ, Trapani JA (2001) Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol 22:409CrossRefPubMed

46.

Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166:3890PubMed

47.

Triebel F, Jitsukawa S, baixeras E, Roman-Roman S, Genevee C, Viegas-Pequinot E, Hercend T (1990) LAG-3, a novel lymphocyte activation gene related to CD4. J Exp Med 171:1393PubMed

48.

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev 3:133CrossRefPubMed

49.

Yip YL, Ward RL (2002) Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 50:569CrossRefPubMed

50.

Yip YL, Smith G, Koch J, Dubel S, Ward RL (2001) Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-erbb-2 monoclonal antibodies: implications for vaccine design. J Immunol 166:5271PubMed

Title: Immunological inhibition of carcinogenesis
Authors: Michela Spadaro
Stefania Lanzardo
Claudia Curcio
Guido Forni
Federica Cavallo
Publication date: 01-03-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0483-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2004

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors

The use of gene function to identify the rate-limiting steps controlling cell fate

Tetraspanins connect several types of Ig proteins: IgM is a novel component of the tetraspanin web on B-lymphoid cells

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer

Identification of tumour antigens by serological analysis of cDNA expression cloning

Natural killer lymphocytes: biology, development, and function

Keynote webinar | Spotlight on antibody–drug conjugates in cancer